Payment overview · 2025
General Payments
$105.08
5 reported records · 4 companies
Healthcare provider profile · identity verified
John Eric Fleming, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PADUCAH, KY · NPI 1235511601
Verified facts
What the public records show
CMS Open Payments records show John Eric Fleming, M.D. received $105.08 in general payments during 2025 across 5 reported records.
Novo Nordisk Inc accounted for 33.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.78 | 33.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.81 | 28.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $25.23 | 24.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.26 | 14.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $105.08 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.81 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 79 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 516 | 167 |
| Levothyroxine Sodium | Levothyroxine Sodium | 468 | 131 |
| Lisinopril | Lisinopril | 389 | 118 |
| Losartan Potassium | Losartan Potassium | 365 | 104 |
| Pantoprazole Sodium | Pantoprazole Sodium | 343 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 329 | 116 |
| Metoprolol Succinate | Metoprolol Succinate | 319 | 95 |
| Hydrochlorothiazide | Hydrochlorothiazide | 305 | 98 |
| Omeprazole | Omeprazole | 235 | 69 |
| Gabapentin | Gabapentin | 232 | 66 |
| Eliquis | Apixaban | 218 | 40 |
| Metformin Hcl Er | Metformin Hcl | 187 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 183 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 176 | 58 |
| Simvastatin | Simvastatin | 175 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 157 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 153 | 61 |
| Citalopram Hbr | Citalopram Hydrobromide | 152 | 42 |
| Furosemide | Furosemide | 149 | 58 |
| Carvedilol | Carvedilol | 143 | 45 |
| Buspirone Hcl | Buspirone Hcl | 139 | 42 |
| Potassium Chloride | Potassium Chloride | 134 | 39 |
| Jardiance | Empagliflozin | 131 | 32 |
| Lorazepam | Lorazepam | 131 | 30 |
| Glipizide Er | Glipizide | 126 | 39 |
| Alprazolam | Alprazolam | 117 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 117 | 35 |
| Tramadol Hcl | Tramadol Hcl | 113 | 37 |
| Metformin Hcl | Metformin Hcl | 111 | 34 |
| Allopurinol | Allopurinol | 110 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 37 |
| Meloxicam | Meloxicam | 108 | 36 |
| Synthroid | Levothyroxine Sodium | 107 | 32 |
| Spironolactone | Spironolactone | 106 | 31 |
| Alendronate Sodium | Alendronate Sodium | 105 | 30 |
| Irbesartan | Irbesartan | 105 | 30 |
| Montelukast Sodium | Montelukast Sodium | 103 | 33 |
| Clonidine Hcl | Clonidine Hcl | 97 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 96 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 89 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 20 |
| Ramipril | Ramipril | 86 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 86 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 26 |
| Trazodone Hcl | Trazodone Hcl | 80 | 26 |
| Ozempic | Semaglutide | 79 | 20 |
| Pregabalin | Pregabalin | 79 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 79 | 24 |
| Cefdinir | Cefdinir | 78 | 66 |
| Sertraline Hcl | Sertraline Hcl | 74 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 73 | 14 |
| Famotidine | Famotidine | 71 | 26 |
| Nifedipine Er | Nifedipine | 67 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 66 | 22 |
| Diazepam | Diazepam | 65 | 13 |
| Finasteride | Finasteride | 65 | 17 |
| Enalapril Maleate | Enalapril Maleate | 61 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 16 |
| Trulicity | Dulaglutide | 57 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 56 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 20 |
| Warfarin Sodium | Warfarin Sodium | 54 | 16 |
| Prednisone | Prednisone | 52 | 34 |
| Azithromycin | Azithromycin | 51 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 18 |
| Atenolol | Atenolol | 49 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 18 |
| Temazepam | Temazepam | 46 | 11 |
| Celecoxib | Celecoxib | 44 | 18 |
| Terazosin Hcl | Terazosin Hcl | 44 | 11 |
| Azelastine Hcl | Azelastine Hcl | 43 | 15 |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 11 |
| Methylprednisolone | Methylprednisolone | 36 | 32 |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Sucralfate | Sucralfate | 36 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 36 | suppressed |
| Baclofen | Baclofen | 35 | 11 |
| Candesartan Cilexetil | Candesartan Cilexetil | 35 | 11 |
| Ezetimibe | Ezetimibe | 35 | 11 |
| Glimepiride | Glimepiride | 34 | suppressed |
| Glipizide | Glipizide | 34 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 13 |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 31 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | suppressed |
| Bumetanide | Bumetanide | 30 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | 12 |
| Meclizine Hcl | Meclizine Hcl | 28 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 21 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 14 |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Nystatin | Nystatin | 24 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 13 |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Colchicine | Colchicine | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Auvelity | Dextromethorphan Hbr/Bupropion | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $105.08 · 5 records | Novo Nordisk Inc | AREXVY, Dexcom G6 Transmitter, Ozempic, REPATHA, Rybelsus, SHINGRIX, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error